KIF11 and glioblastoma: Thus, for a KIF11 inhibitor to be therapeutically active in GBM, it needs not only to cross the BBB, but be retained within both brain and tumor at effective concentrations for considerable periods of time in order to target a substantial proportion of tumor cells when they are vulnerable.